Discovery of a new series of PI3K-6 inhibitors from Virtual Screening

PI3K-6 mediates key immune cell signaling pathways and is a target of interest for treatment of oncological and immunological disorders. Here we describe the discovery and optimization of a novel series of PI3K-6 selective inhibitors. We first identified hits containing an isoindolinone scaffold using a combined ligand- and receptorbased virtual screening workflow, and then improved potency and selectivity guided by structural data and modeling. Careful optimization of molecular properties led to compounds with improved permeability and pharmacokinetic profile, and high potency in a whole blood assay.

Automated summary

This study describes the discovery and optimization process of a novel series of PI3K-6 selective inhibitors, which were identified using a virtual screening workflow and improved for potency and selectivity guided by structural data. The careful optimization of molecular properties led to compounds with high potency in a whole blood assay.